Perforomist



Indications and Reactions:

Role Indications Reactions
Primary
Chronic Obstructive Pulmonary Disease 47.4%
Asthma 17.1%
Emphysema 7.9%
Dyspnoea 5.3%
Hypersensitivity 2.6%
Migraine 2.6%
Anxiety 2.0%
Bronchiectasis 2.0%
Respiratory Disorder 2.0%
Blood Pressure Increased 1.3%
Fibromyalgia 1.3%
Hypertension 1.3%
Nausea 1.3%
Osteoarthritis 1.3%
Pain 1.3%
Arthritis 0.7%
Blood Cholesterol 0.7%
Blood Cholesterol Increased 0.7%
Bronchitis 0.7%
Bronchitis Chronic 0.7%
Dyspnoea 22.2%
Cough 11.1%
Tremor 9.5%
Dizziness 6.3%
Pneumonia 4.8%
Somnolence 4.8%
Alopecia 3.2%
Candidiasis 3.2%
Chronic Obstructive Pulmonary Disease 3.2%
Drug Effect Decreased 3.2%
Dry Mouth 3.2%
Fatigue 3.2%
Headache 3.2%
Heart Rate Irregular 3.2%
Insomnia 3.2%
Muscle Spasms 3.2%
Rash 3.2%
Wheezing 3.2%
Abdominal Discomfort 1.6%
Abdominal Pain 1.6%
Secondary
Chronic Obstructive Pulmonary Disease 30.6%
Asthma 20.7%
Emphysema 13.5%
Osteoarthritis 6.3%
Osteoporosis 6.3%
Pain 6.3%
Dyspnoea 2.7%
Hypersensitivity 2.7%
Migraine 2.7%
Anxiety 1.8%
Bronchitis 1.8%
Bronchitis Chronic 1.8%
Respiratory Disorder 1.8%
Blood Pressure Increased 0.9%
Dizziness 18.9%
Dyspnoea 10.8%
Tremor 10.8%
Somnolence 8.1%
Fatigue 5.4%
Night Sweats 5.4%
Wheezing 5.4%
Aphthous Stomatitis 2.7%
Chest Pain 2.7%
Chronic Obstructive Pulmonary Disease 2.7%
Cough 2.7%
Dementia Alzheimer's Type 2.7%
Drug Ineffective 2.7%
Dysphonia 2.7%
Dysuria 2.7%
Nausea 2.7%
Nervousness 2.7%
Off Label Use 2.7%
Pulmonary Congestion 2.7%
Rash 2.7%
Concomitant
Drug Use For Unknown Indication 22.9%
Chronic Obstructive Pulmonary Disease 14.8%
Product Used For Unknown Indication 11.8%
Asthma 10.3%
Cardiac Disorder 6.1%
Hypertension 5.4%
Emphysema 3.7%
Dyspnoea 2.8%
Prophylaxis 2.6%
Pulmonary Arterial Hypertension 2.6%
Hypersensitivity 2.2%
Osteoporosis 2.0%
Cardiac Failure Congestive 1.8%
Depression 1.8%
Gastrooesophageal Reflux Disease 1.8%
Lung Disorder 1.7%
Blood Cholesterol Increased 1.5%
Muscle Spasms 1.5%
Rheumatoid Arthritis 1.5%
Angina Pectoris 1.3%
Pneumonia 16.1%
Dyspnoea 8.9%
Drug Ineffective 5.4%
Fatigue 5.4%
Malaise 5.4%
Multiple Sclerosis Relapse 5.4%
Unevaluable Event 5.4%
Vomiting 5.4%
Anticonvulsant Drug Level Increased 3.6%
Back Pain 3.6%
Chronic Obstructive Pulmonary Disease 3.6%
Fluid Retention 3.6%
Gait Disturbance 3.6%
Nasopharyngitis 3.6%
Oedema Peripheral 3.6%
Off Label Use 3.6%
Palpitations 3.6%
Product Quality Issue 3.6%
Renal Cancer 3.6%
Senile Dementia 3.6%